Novel vaccine works a treat for ragweed allergies

    loading  Checking for direct PDF access through Ovid

Abstract

The novel ragweed allergen 1018 ISS conjugate [Tolamba] is effective in reducing the allergic response in patients with seasonal ragweed allergies, according to a phase II/III trial presented at the 62nd Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) [Miami Beach, Florida, US; March 2006]. The randomised, double-blind, multicentre trial, conducted over two ragweed seasons and involving more than 450 patients with seasonal ragweed allergies, showed that a single 6-week course of Tolamba prior to the first ragweed season significantly improved the patient-assessed total nasal symptom score (TNSS) from baseline, compared with placebo, during both allergen seasons.

Related Topics

    loading  Loading Related Articles